PF-06273340

• Description :

  PF-06273340 is a potent, selective, orally bioavailable and peripherally restricted pan Trk inhibitor[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Trk Receptor

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pf-06273340.html

• Purity :

  98.8

• Solubility :

  DMSO : 20 mg/mL (ultrasonic; warming)

• Smiles :

  O=C(NC1=CC(C(C2=CN(C(C)(C)CO)C3=NC(N)=NC=C32)=O)=CN=C1)CC4=NC=C(Cl)C=C4

• Molecular Formula :

  C23H22ClN7O3

• Molecular Weight :

  479.92

• Precautions :

  H302

• References & Citations :

  [1]Skerratt SE, et al. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  Trk

• CAS Number :

  [1402438-74-7]